Precisely Targeted Nano-Controller of PD-L1 Level for Non-Small Cell Lung Cancer Spinal Metastasis Immunotherapy

Area of Science:

• Oncology
• Nanomedicine
• Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) are vital for non-small cell lung cancer (NSCLC) treatment.
• Many NSCLC patients, particularly those with spinal metastasis (NSCLC-SM), show resistance to anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) therapies.
• A targeted drug delivery system for NSCLC-SM is needed to overcome PD-L1 resistance.

Purpose of the Study:

• To develop a PD-L1 targeting nano-controller for NSCLC-SM.
• To investigate the potential of RGDyK as a PD-L1 inhibitor and NSCLC-SM targeting peptide.
• To evaluate the synergistic effects of photodynamic therapy (PDT) and immunotherapy in a preclinical NSCLC-SM model.

Main Methods:

• Identified integrin β3 (β3-int) upregulation in NSCLC-SM.
• Synthesized RGDyK-modified, zinc protoporphyrin (ZnPP)-loaded mesoporous silicon nanoparticles (ZnPP@MSN-RGDyK).
• Assessed nanoparticle targeting of β3-int, PD-L1 inhibition, PDT efficiency, and immunotherapeutic effects in an NSCLC-SM mouse model.

Main Results:

• RGDyK was found to inhibit PD-L1 by promoting its ubiquitination.
• ZnPP@MSN-RGDyK nanoparticles effectively targeted β3-int in NSCLC-SM.
• The fabricated nanoparticles demonstrated high PDT efficiency and significant immunotherapeutic effects in vivo.

Conclusions:

• ZnPP@MSN-RGDyK nanoparticles represent a novel strategy for NSCLC-SM treatment.
• This nano-controller shows potential for overcoming resistance to PD-1/PD-L1 therapies.
• The findings suggest ZnPP@MSN-RGDyK as a promising immunotherapeutic agent for NSCLC-SM.